Denali Therapeutics Inc.

The fourth quarter of 2024 was not without setbacks for AbbVie, which took a $3.5bn impairment against the value of its 2023 buyout of Cerevel after a Phase II failure in schizophrenia, but the pharma

The amyotrophic lateral sclerosis (ALS) pipeline has suffered a series of setbacks recently and two separate candidates from AbbVie/Calico Life Sciences and Denali Therapeutics that have the same of m

The week before the annual J.P. Morgan Healthcare Conference always brings a flurry of new venture capital financings and the tradition continued in 2025, including Aviceda Therapeutics with a $207.5m

Sanofi 's multiple sclerosis pipeline, which has shown promise of late, has suffered a setback with the news that oditrasertib, partnered with Denali Therapeutics Inc. , has failed in a mid-stage stu